Kimberly-Clark Corp. shares fell the most in a quarter century after agreeing to buy Kenvue Inc., whose biggest product, Tylenol, is in the crosshairs of the White House.

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue for $48.7 billion, including debt. Shares of Kenvue, a Johnson & Johnson spin-off best known for its Tylenol,

Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.

Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company.

Kimberly-Clark’s third-quarter profit fell 51% as a result of divestitures, business exits and recent tariffs, although sales ticked up slightly.